Wealth Enhancement Advisory Services LLC Takes $202,000 Position in Qiagen N.V. (NYSE:QGEN)

Wealth Enhancement Advisory Services LLC bought a new stake in Qiagen N.V. (NYSE:QGEN) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 4,540 shares of the company’s stock, valued at approximately $202,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Brown Brothers Harriman & Co. bought a new position in Qiagen during the 4th quarter valued at approximately $37,000. EverSource Wealth Advisors LLC raised its position in Qiagen by 152.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock valued at $39,000 after purchasing an additional 526 shares during the last quarter. Smartleaf Asset Management LLC raised its position in shares of Qiagen by 148.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company’s stock worth $63,000 after acquiring an additional 835 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Qiagen by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company’s stock worth $111,000 after acquiring an additional 2,204 shares in the last quarter. Finally, Globeflex Capital L P bought a new position in shares of Qiagen in the 4th quarter worth approximately $151,000. Institutional investors own 70.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Redburn Atlantic downgraded Qiagen from a “buy” rating to a “neutral” rating in a research note on Friday, April 4th. Wall Street Zen upgraded Qiagen from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 15th. Baird R W downgraded Qiagen from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Finally, Robert W. Baird upped their price target on Qiagen from $42.00 to $43.00 and gave the stock a “neutral” rating in a research note on Monday, April 21st. Seven investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $48.42.

Qiagen Stock Down 1.8%

Shares of NYSE:QGEN opened at $46.58 on Wednesday. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $49.30. The business has a 50 day simple moving average of $43.26 and a two-hundred day simple moving average of $42.29. The firm has a market capitalization of $10.36 billion, a PE ratio of 116.80, a price-to-earnings-growth ratio of 2.42 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.37 and a quick ratio of 2.83.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The business had revenue of $483.46 million during the quarter, compared to analyst estimates of $465.66 million. During the same quarter in the previous year, the business earned $0.44 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities analysts predict that Qiagen N.V. will post 2.26 EPS for the current year.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.